STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Diamyd Medical AB (NASDAQ:DMYDY) (STO:DIAMB):
September 1, 2006 – August 31, 2007
Type 1 diabetes project showing steady progress towards phase III trials.
Continued strong results from a Phase II trial were presented after 21 months follow-up, with a significant difference in efficacy between the Diamyd® group and the placebo group (September 2007).
Following a filing of an End of Phase II briefing package and a meeting with the US FDA in January 2007, the plan is to submit an IND application before the end of 2007 to initiate a Phase III program.
